The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network

The Clinical Course of Portopulmonary Hypertension and Outcomes With Endothelin Receptor Antagonist Treatment: Observational Study of Data From the US Organ Procurement and Transplantation Network

Background. Portopulmonary hypertension (PoPH) occurs in patients with advanced liver disease and can be a contraindication to liver transplant (LT). Improvement of hemodynamic parameters with pulmonary arterial hypertension (PAH) therapies (including endothelin receptor antagonists [ERAs]) may help...

Full description

Bibliographic Details
Main Authors: Hilary M. DuBrock, MD, Arun Jose, MD, Sarah Arendse, MSc, Nicolas Martin, MSc, Sean Studer, MD, Daniel Rosenberg, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2024-03-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001586

Internet

http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001586

Similar Items